Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Family caregivers

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Family caregivers. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2015-001216-35 Sponsor Protocol Number: CONCERTAATT4086 Start Date*: 2015-04-24
    Sponsor Name:Johnson & Johnson Taiwan Ltd
    Full Title: From Immediate-release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023263-18 Sponsor Protocol Number: A0081105 Start Date*: 2013-06-12
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC-CLONIC SEIZURES
    Medical condition: Primary Generalised Tonic Clonic Seizures
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004852 10018101 Generalised tonic-clonic seizures HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) HU (Completed) LT (Completed) NL (Completed) SK (Completed) AT (Completed) BG (Completed) ES (Completed) PL (Completed) EE (Completed) GR (Completed) BE (Completed) HR (Completed) DK (Completed) PT (Not Authorised) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000176-33 Sponsor Protocol Number: DMD03 Start Date*: 2011-02-14
    Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR
    Full Title: Cell Therapy Of Duchenne Muscular Dystrophy by intra-arterial delivery of HLA-identical allogeneic mesoangioblasts
    Medical condition: Duchenne Muscolar Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10013801 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005534-15 Sponsor Protocol Number: PRO-GLY-002/E2013 Start Date*: 2021-04-01
    Sponsor Name:Proveca Pharma LTD
    Full Title: Double-blind, placebo-controlled, randomized clinical trial comparing the efficacy and safety of Sialanar plus oral rehabilitation against placebo plus oral rehabilitation for children and adolesce...
    Medical condition: Severe sialorrhoea and neurodisabilties in children
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001765-25 Sponsor Protocol Number: CASM981CUS09 Start Date*: 2017-09-28
    Sponsor Name:Novartis
    Full Title: An Investigation of the Safety and Efficacy of Elidel® 1% Cream in Atopic Disease Modification, Assessed in a 3-year Randomized Doubleblind Vehicle Controlled Phase to Evaluate Effects on Atopic De...
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002001-21 Sponsor Protocol Number: 3597 Start Date*: 2020-05-15
    Sponsor Name:King's College London [...]
    1. King's College London
    2. University College Dublin
    Full Title: BETTER-B: BETter TreatmEnts for Refractory Breathlessness. An International, Multicentre, Randomised Controlled Pragmatic Trial of Mirtazapine to alleviate Breathlessness in Palliative and End of L...
    Medical condition: Refractory breathlessness in patients diagnosed with chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) DE (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002051-42 Sponsor Protocol Number: R119861 Start Date*: 2019-10-25
    Sponsor Name:University of Manchester
    Full Title: A phase I-II, study of autologous CD34+ haematopoietic stem cells transduced ex vivo with CD11b lentiviral vector encoding for human SGSH in patients with mucopolysaccharidosis type IIIA (MPS IIIA,...
    Medical condition: MPS IIIA, mucopolysaccharidosis type IIIA
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10028093 Mucopolysaccharidosis PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2012-005678-76 Sponsor Protocol Number: AIFANumberFARM94793N Start Date*: 2013-08-30
    Sponsor Name:ALLEGRIA onlus
    Full Title: Twenty-four month, multicenter, prospective, randomized, double-blind, placebo controlled, parallel-group study to evaluate the efficacy, safety, tolerability, and cost-effectiveness of allergen sp...
    Medical condition: Allergic asthma to house dust mites
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10003558 Asthma extrinsic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001169-26 Sponsor Protocol Number: SNR-04 Start Date*: 2019-05-02
    Sponsor Name:SyneuRx International (Taiwan) Corp
    Full Title: An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (sodium benzoate), a D-Amino Acid Oxidase Inhibitor, as...
    Medical condition: Treatment for Schizophrenia in Adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-000906-20 Sponsor Protocol Number: LUM001-601 Start Date*: 2015-05-13
    Sponsor Name:Shire Human Genetic Therapies Inc
    Full Title: An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients with Alagille Syndrome (ALGS) ...
    Medical condition: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    17.1 10010331 - Congenital, familial and genetic disorders 10053870 Alagille syndrome PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003943-20 Sponsor Protocol Number: DX-2930-03 Start Date*: 2016-03-31
    Sponsor Name:Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
    Full Title: HELP Study™: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX 2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
    Medical condition: Hereditary angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004850 10075280 Hereditary angioedema attack LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005255-27 Sponsor Protocol Number: DX-2930-04 Start Date*: 2016-11-30
    Sponsor Name:Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)
    Full Title: HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)
    Medical condition: Type I and Type II Hareditary Angioedema (HAE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075280 Hereditary angioedema attack LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002804-14 Sponsor Protocol Number: ZX008-1503 Start Date*: 2016-11-08
    Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc
    Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome
    Medical condition: Seizures associated with Dravet syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) DK (Completed) ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-001619-65 Sponsor Protocol Number: TV46000-CNS-30072 Start Date*: 2018-11-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneou...
    Medical condition: Maintenance treatment of schizophrenia in patients currently treated with oral antipsychotics
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2004-001308-11 Sponsor Protocol Number: F1D-XM-HGLW Start Date*: 2004-08-19
    Sponsor Name:Lilly.S.A.
    Full Title: Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies
    Medical condition: to compare the efficacy in the prevention of relapse to manic, depressive, or mixed episodes in two groups of bipolar I patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015170-35 Sponsor Protocol Number: 5137 Start Date*: 2012-01-27
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Multicentre UK Study of the Acetylcholinesterase Inhibitor Donepezil in Early Dementia Associated with Parkinson's Disease (MUSTARDD-PD)
    Medical condition: Parkinson's disease with mild dementia (PDD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003447-28 Sponsor Protocol Number: XPF-009-302 Start Date*: 2021-10-29
    Sponsor Name:Xenon Pharmaceuticals Inc.
    Full Title: An Open-Label Extension Study of XEN496 in Pediatric Subjects with KCNQ2 Developmental and Epileptic Encephalopathy
    Medical condition: KCNQ2 Developmental and Epileptic Encephalopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2023-000185-34 Sponsor Protocol Number: VAL1221-ITLAFORA-01 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA USL DI BOLOGNA
    Full Title: A SINGLE ARM, OPEN-LABEL, PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF VAL-1221 ON SUBJECTS WITH LAFORA DISEASE
    Medical condition: patients with mid- to late stage Lafora Desease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10054030 Lafora's myoclonic epilepsy PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-003331-36 Sponsor Protocol Number: FER-Loxapine-2015-01 Start Date*: 2016-03-16
    Sponsor Name:FERRER INTERNACIONAL SA
    Full Title: A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of self-administered ADASUVE(R) (Staccato loxapine for inhalation) in Agitated Patients outside the hospital setting
    Medical condition: Mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10001497 Agitation PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-013648-35 Sponsor Protocol Number: PENTA 18 Start Date*: 2010-06-23
    Sponsor Name:PENTA Foundation
    Full Title: KONCERT A Kaletra ONCE daily Randomised Trial of the pharmacokinetics, safety and efficacy of twice-daily versus once-daily lopinavir/ritonavir tablets dosed by weight as part of combination antir...
    Medical condition: Paediatric HIV-1 Infection
    Disease: Version SOC Term Classification Code Term Level
    12 10021881 HIV-1 Infection SOC
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) NL (Ongoing) FR (Completed) GB (Completed) ES (Completed) PT (Completed) BE (Completed) DE (Completed)
    Trial results: Removed from public view
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 14:15:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA